Matthew Kane's Insider Trades & SAST Disclosures
Matthew Kane's most recent trade in Flexsteel Industries, Inc. was a trade of 1,316 Common Stock done . Disclosure was reported to the exchange on Dec. 14, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew Kane.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Flexsteel Industries, Inc. | Kaness A. Matthew | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 1,316 | 45,016 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2023 | 1,184 | 43,700 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,161 | 42,516 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 1,138 | 41,355 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 1,234 | 40,217 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 15.69 per share. | 15 Sep 2022 | 1,115 | 38,983 (0%) | 0% | 15.7 | 17,494 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 18.45 per share. | 16 Jun 2022 | 949 | 37,868 (0%) | 0% | 18.4 | 17,509 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 3,486 | 10,458 | - | - | Restricted Stock Units | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 3,486 | 351,967 (2%) | 0% | - | Common Shares | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 19.57 per share. | 10 Mar 2022 | 894 | 36,919 (0%) | 0% | 19.6 | 17,496 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 13,944 | 13,944 | - | - | Restricted Stock Units | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 30.50 per share. | 09 Dec 2021 | 574 | 36,025 (0%) | 0% | 30.5 | 17,507 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 06 Oct 2021 | 128,160 | 131,928 (1%) | 0% | 2.7 | 346,032 | Common Shares |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 29.88 per share. | 05 Oct 2021 | 112 | 35,451 (0%) | 0% | 29.9 | 3,347 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 34.98 per share. | 09 Sep 2021 | 501 | 35,339 (0%) | 0% | 35.0 | 17,525 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 04 Aug 2021 | 11,299 | 145,081 (1%) | 0% | 2.7 | 30,507 | Common Shares |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 1,854 | 0 | - | - | Restricted Stock Units | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 1,854 | 133,782 (1%) | 0% | 0 | Common Shares | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 39.22 per share. | 16 Jul 2021 | 85 | 34,838 (0%) | 0% | 39.2 | 3,334 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 43.66 per share. | 17 Jun 2021 | 400 | 34,752 (0%) | 0% | 43.7 | 17,464 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 1,312 | 1,312 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 763 | 763 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 13 May 2021 | 21,514 | 2,023,272 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 21,514 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 13 May 2021 | 9,675 | 2,013,597 (3%) | 0% | 9.0 | 86,688 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 07 May 2021 | 21,514 | 1,999,732 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 21,514 | 21,514 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 21,514 | 43,028 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 07 May 2021 | 21,514 | 2,011,504 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 07 May 2021 | 9,746 | 2,001,758 (3%) | 0% | 8.3 | 80,405 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 07 May 2021 | 9,742 | 1,989,990 (3%) | 0% | 8.6 | 83,489 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 5,254 | 5,254 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2021 | 13,422 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 21 Apr 2021 | 13,422 | 1,978,218 (3%) | 0% | 1.2 | 15,838 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 Apr 2021 | 21,514 | 1,974,537 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 21,514 | 64,542 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 12 Apr 2021 | 9,741 | 1,964,796 (3%) | 0% | 8.7 | 84,454 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 21,514 | 107,570 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 08 Apr 2021 | 21,514 | 1,962,760 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 08 Apr 2021 | 21,514 | 1,950,982 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 21,514 | 86,056 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.87 per share. | 08 Apr 2021 | 9,737 | 1,953,023 (3%) | 0% | 8.9 | 86,367 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 08 Apr 2021 | 9,736 | 1,941,246 (3%) | 0% | 9 | 87,624 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 33.54 per share. | 01 Apr 2021 | 99 | 34,352 (0%) | 0% | 33.5 | 3,320 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 21,514 | 129,084 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 Mar 2021 | 21,514 | 1,939,180 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.36 per share. | 12 Mar 2021 | 9,712 | 1,929,468 (3%) | 0% | 11.4 | 110,328 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,514 | 150,598 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,514 | 172,112 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 10 Mar 2021 | 21,514 | 1,927,377 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 10 Mar 2021 | 21,514 | 1,915,573 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.38 per share. | 10 Mar 2021 | 9,711 | 1,917,666 (3%) | 0% | 11.4 | 110,511 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.79 per share. | 10 Mar 2021 | 9,710 | 1,905,863 (3%) | 0% | 11.8 | 114,481 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 33.27 per share. | 04 Mar 2021 | 526 | 34,252 (0%) | 0% | 33.3 | 17,500 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 18 Feb 2021 | 21,514 | 1,899,151 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 21,514 | 193,626 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.23 per share. | 18 Feb 2021 | 9,705 | 1,889,446 (3%) | 0% | 12.2 | 118,692 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Feb 2021 | 21,514 | 1,887,342 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Feb 2021 | 21,514 | 1,875,525 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 21,514 | 215,140 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 21,514 | 236,654 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.28 per share. | 16 Feb 2021 | 9,705 | 1,877,637 (3%) | 0% | 12.3 | 119,177 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.30 per share. | 16 Feb 2021 | 9,697 | 1,865,828 (3%) | 0% | 13.3 | 128,970 | Common Stock |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 1,854 | 3,768 (0%) | 0% | - | Common Shares | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 1,854 | 0 | - | - | Restricted Stock Units | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 1,382 | 1,914 (0%) | 0% | - | Common Shares | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 1,382 | 0 | - | - | Restricted Stock Units | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 532 | 532 (0%) | 0% | - | Common Shares | |
| Akerna Corp | Matthew R. Kane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 532 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 21,515 | 258,168 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 26 Jan 2021 | 21,515 | 1,863,708 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.37 per share. | 26 Jan 2021 | 9,697 | 1,854,011 (3%) | 0% | 13.4 | 129,649 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 22 Jan 2021 | 21,514 | 1,840,592 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 21,514 | 279,683 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 21,514 | 301,197 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 22 Jan 2021 | 21,514 | 1,851,888 (3%) | 0% | 0.0 | 861 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.53 per share. | 22 Jan 2021 | 10,218 | 1,830,374 (3%) | 0% | 13.5 | 138,250 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.74 per share. | 22 Jan 2021 | 9,695 | 1,842,193 (3%) | 0% | 13.7 | 133,209 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 33.42 per share. | 07 Jan 2021 | 66 | 33,726 (0%) | 0% | 33.4 | 2,206 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 33.06 per share. | 10 Dec 2020 | 378 | 33,660 (0%) | 0% | 33.1 | 12,497 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 27.28 per share. | 20 Nov 2020 | 7,000 | 33,282 (0%) | 0% | 27.3 | 190,960 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 27.85 per share. | 21 Oct 2020 | 27 | 26,282 (0%) | 0% | 27.9 | 752 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 21.33 per share. | 16 Sep 2020 | 8,000 | 25,716 (0%) | 0% | 21.3 | 170,640 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 23.25 per share. | 16 Sep 2020 | 538 | 26,254 (0%) | 0% | 23.3 | 12,509 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 13.51 per share. | 31 Aug 2020 | 37 | 17,716 (0%) | 0% | 13.5 | 500 | Common Stock |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Purchase of securities on an exchange or from another person at price $ 16.73 per share. | 28 Aug 2020 | 5,000 | 17,679 (0%) | 0% | 16.7 | 83,650 | Common Stock |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 1,743 | 1,743 | - | - | Employee Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 202,391 | 202,391 | - | - | Employee Stock Option (Right to Buy) | |
| Flexsteel Industries, Inc. | Matthew A. Kaness | Director | Grant, award, or other acquisition of securities at price $ 11.93 per share. | 08 Jun 2020 | 1,047 | 12,679 (0%) | 0% | 11.9 | 12,491 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges